Literature DB >> 10146913

Developing the QALY concept: exploring the problems of data acquisition.

J Coast1.   

Abstract

Mesh:

Year:  1993        PMID: 10146913     DOI: 10.2165/00019053-199304040-00002

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  24 in total

1.  EuroQol--a new facility for the measurement of health-related quality of life.

Authors: 
Journal:  Health Policy       Date:  1990-12       Impact factor: 2.980

2.  Reprocessing data to form QALYs.

Authors:  J Coast
Journal:  BMJ       Date:  1992-07-11

3.  Preference based outcome measures for economic evaluation of drug interventions: quality adjusted life years (QALYs) versus healthy years equivalents (HYEs).

Authors:  A Mehrez; A Gafni
Journal:  Pharmacoeconomics       Date:  1992-05       Impact factor: 4.981

Review 4.  The use of QALYs in health care decision making.

Authors:  G Loomes; L McKenzie
Journal:  Soc Sci Med       Date:  1989       Impact factor: 4.634

5.  Chiropody and the QALY: a case study in assigning categories of disability and distress to patients.

Authors:  S Bryan; D Parkin; C Donaldson
Journal:  Health Policy       Date:  1991-07       Impact factor: 2.980

6.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

7.  Some guidelines on the use of cost effectiveness league tables.

Authors:  J Mason; M Drummond; G Torrance
Journal:  BMJ       Date:  1993-02-27

8.  Economic evaluation of neonatal intensive care of very-low-birth-weight infants.

Authors:  M H Boyle; G W Torrance; J C Sinclair; S P Horwood
Journal:  N Engl J Med       Date:  1983-06-02       Impact factor: 91.245

9.  Prioritising waiting lists.

Authors:  C Gudex; A Williams; M Jourdan; R Mason; J Maynard; R O'Flynn; M Rendall
Journal:  Health Trends       Date:  1990

10.  Is screening for abdominal aortic aneurysm worthwhile?

Authors:  J G Russell
Journal:  Clin Radiol       Date:  1990-03       Impact factor: 2.350

View more
  2 in total

Review 1.  The cost of Alzheimer's disease. Will drug treatment ease the burden?

Authors:  W Max
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

2.  Measuring patient benefit from botulinum toxin in the treatment of dystonia. Feasibility of cost-utility analysis.

Authors:  C M Gudex; M R Hawthorne; A G Butler; P O Duffey
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.